Spectral Medical Inc.

TSX:EDT.TO

Medical - Diagnostics & Research

Healthcare
$1.04 -1.45%

-$0.02 today

Market cap
$306.00M
Beta
0.23
P/E (TTM)
-10.5
EPS (TTM)
-$0.13
52W Low $0.77High $1.84

Volume 0.02M

Average 0.06M

EDT.TO Debt Repayment

Cash used to repay borrowings during the period.

Spectral Medical Inc.TSX: EDT.TO

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment grows, but more slowly than its trailing trend

Q1 FY2026 debt repayment of CA$38K (cash outflow) rose 0.0% year over year, behind the +97.4% change in trailing-twelve-month debt repayment. Over 3 fiscal years it compounded at +37.6% a year.

Context

  • Debt repayment amounted to 395.9% of revenue in FY2025, down 30.3 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +97.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$38K-100.4% QoQ
Last fiscal yearDec 2025
CA$9.67M-0.8% YoY
LTMMar 2026
CA$19.22M+97.4% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-0.8%——
3-year CAGR+37.6%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

CAD · from the cash flow

Latest · FY2025
9.67M CAD
Year-over-year change
-0.8%

Debt Repayment vs competitors

How EDT.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +97.4% is the 3rd highest of 7, against a peer median of +19.7%.
  • Debt repayment amounts to 696.2% of revenue for EDT.TO, versus a peer median of 12.4%.
EDT.TO Competitors
Debt Repayment for EDT.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$41.44M CAD-81.2%—13.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$40.19M USD-201.1%+759.9%78.9%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$19.82M USD——38.7%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$19.22M CAD+97.4%+37.6%696.2%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$7.59M CAD+91.9%+87.6%11.4%
PRN.TOProfound Medical Corp.LTM Mar 2026$1.03M USD-52.4%—5.5%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD+100.0%——
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$0 CAD+100.0%—0.0%
Peer median (excluding EDT.TO) —+19.7%+423.8%12.4%

Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.79M)(11.25M)(15.66M)(15.4M)(47.69M)
Depreciation & Amortization294K272K218K251K250K
Deferred Income Tax00000
Stock-Based Compensation1.26M1.2M1.49M1.68M2.12M
Change in Working Capital(1.76M)579K(406K)1.01M(189K)
Accounts Receivables55K(877K)870K(265K)246K
Inventory(51K)(47K)(26K)137K(148K)
Accounts Payables(1.11M)1.65M(267K)(51K)(265K)
Other Working Capital(656K)(142K)(983K)1.19M(22K)
Other Non-Cash Items288K(698K)3.64M3.64M33.88M
Operating Cash Flow(8.7M)(9.9M)(10.72M)(8.82M)(9.52M)
Capital Expenditures(483K)(33K)(185K)(27K)(195K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities158K0000
Investing Cash Flow(325K)(33K)(185K)(27K)(195K)
Debt Repayment(113K)3.71M3.93M9.74M9.67M
Common Stock Issued10M4.03M01.15M3.4M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.28M1.72M1.51M(2.02M)(155K)
Financing Cash Flow12.17M9.46M5.44M8.88M12.91M
Effect of Forex Changes(56K)0000
Net Change in Cash3.08M(476K)(5.46M)36K1.08M
Free Cash Flow(9.18M)(9.93M)(10.91M)(8.85M)(9.72M)

Spectral Medical Inc.

TSX:EDT.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.